Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 1,492 Shares

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,492 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $11.90, for a total value of $17,754.80. Following the transaction, the senior vice president owned 81,929 shares in the company, valued at $974,955.10. This represents a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Stock Performance

NASDAQ XNCR traded down $1.50 on Thursday, reaching $11.24. The stock had a trading volume of 865,363 shares, compared to its average volume of 685,250. The stock has a market cap of $824.33 million, a P/E ratio of -9.06 and a beta of 0.95. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69. The business’s 50-day moving average price is $12.96 and its 200 day moving average price is $12.91. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.55. The firm had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. Xencor’s revenue for the quarter was down 46.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.62) EPS. As a group, equities analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on XNCR. Wall Street Zen lowered Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Xencor in a research report on Thursday, November 6th. Royal Bank Of Canada upped their price objective on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Monday, December 29th. Finally, Cantor Fitzgerald boosted their price target on shares of Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Xencor presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. boosted its stake in shares of Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,156 shares in the last quarter. GAMMA Investing LLC boosted its position in Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC acquired a new stake in Xencor in the third quarter valued at $44,000. Tower Research Capital LLC TRC raised its stake in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares during the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares in the last quarter.

Xencor News Summary

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Recent quarterly results showed an EPS beat (reported 2/25), and Xencor’s balance sheet remains strong (high quick/current ratios), which limits near‑term financing risk and supports long‑term program funding. MarketBeat: Xencor company page
• Neutral Sentiment: CEO Bassil Dahiyat disclosed a sale of 6,758 shares at an average of $11.90 (≈$80k); the sale reduced his ownership by ~1.18% — notable but relatively small as a percentage of his holdings and possibly routine diversification. InsiderTrades: CEO share sale
• Negative Sentiment: Reported royalty dispute: Alexion (operator of Ultomiris) has cut off U.S. royalty payments to Xencor, and Xencor announced it is revising its Ultomiris royalty revenue forecast — this directly reduces expected near‑term revenue and is the primary negative catalyst for today’s drop. Benzinga: Royalty rift report
• Negative Sentiment: Additional insider sales (SVP Celia Eckert and VP John Desjarlais sold shares the same day) amplify investor concern about insider selling patterns and contributed to negative sentiment. Xencor also posted a formal update on its Ultomiris royalty forecast via its announcement. Yahoo Finance: Xencor royalty forecast change

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.